Compare FLXS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | FULC |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.6M | 285.4M |
| IPO Year | 1995 | 2019 |
| Metric | FLXS | FULC |
|---|---|---|
| Price | $74.99 | $3.77 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | ★ $87.00 | $3.67 |
| AVG Volume (30 Days) | 53.8K | ★ 1.4M |
| Earning Date | 10-26-2026 | 11-17-2026 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ 70.99 | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $459,178,000.00 | N/A |
| Revenue This Year | $3.48 | N/A |
| Revenue Next Year | $5.29 | N/A |
| P/E Ratio | $58.79 | ★ N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $34.50 | $2.83 |
| 52 Week High | $90.65 | $15.74 |
| Indicator | FLXS | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 52.57 |
| Support Level | $72.11 | $3.62 |
| Resistance Level | $78.44 | $3.91 |
| Average True Range (ATR) | 3.59 | 0.07 |
| MACD | -1.34 | 0.01 |
| Stochastic Oscillator | 36.74 | 66.67 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.